Phase 1 trials to begin on Daewoong's IVL3001 hair loss treatment
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
Daewoong Pharmaceutical won approval in Australia for Phase 1 clinical trials of the IVL3001 hair loss treatment, the company said Monday.
With permission from Australia’s Therapeutic Goods Administration, the company plans to test the treatment’s efficacy in the first round of clinical trials. The treatment is injected once every three months as opposed to existing drugs, which require daily consumption or use.
“We will offer people who are suffering from hair loss convenience and efficacy by developing injectable version of treatment,” said Jeon Seng-ho, CEO of Daewoong Pharmaceutical. “Daewoong will closely cooperate with our partner companies that own great technologies in order to successfully launch the product.”
In June, Daewoong signed an agreement with Seongnam-based Inventage Lab and Seoul-based Withus Pharmaceutical to codevelop the hair loss treatment. The three companies aim to commercialize the drug in Korea by 2023.
During the development process, Daewoong agreed to lead Phase 3 clinical trials, obtain approvals and sell the product after commercialization. Inventage Lab agreed to lead preclinical trials and Phase 1 clinical trials and provide support for manufacturing, while Withus Pharmaceutical will manufacture the treatment.
The market size of global hair loss treatment market was about 8 trillion won ($6.8 billion) in 2020. It will double in size by 2028, according to data compiled by U.S. market tracker Grand View Research.
BY SARAH CHEA [chea.sarah@joongang.co.kr]
Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.
- Kim Yo-jong extends an olive branch to Moon
- After 512 episodes, Yumi and her cells say their final goodbye
- ‘Squid Game’ is No. 1 among U.S. Netflix viewers
- 'It's Okay to Not Be Okay' nominated for International Emmy Awards
- Young people’s deaths after Pfizer vaccines are new worry
- Long weekends could lead to new wave of infections
- Korean companies renaming themselves to internationalize
- Inha University Hospital starts telemedicine service for foreign residents
- Electric, gas, milk bills — inflation rises all boats
- Narilya Gulmongkolpech earns unanimous praise for role in 'The Medium'